This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I wherein X
1
is (CH
2
)
n
or CO, n is 0 to 2 and R
1
, R
2
, R
3
and R
4
are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.
1
这项发明涉及一般为CRF-1受体拮抗剂的化合物,其表示为公式I,其中X1为(
CH2)n或CO,n为0至2,R1、R2、R3和R4如规范中定义;或其各个异构体、拉氏或非拉氏混合物,或其药用可接受盐。该发明还涉及制备这类化合物的方法,含有这类化合物的药物组合物,以及它们作为治疗剂的使用方法。